Invirsa is a technology company.
Invirsa has raised $10.5M across 3 funding rounds.
Invirsa has raised $10.5M in total across 3 funding rounds.
Invirsa has raised $10.5M in total across 3 funding rounds.
Invirsa's investors include Alumni Ventures, Cincy Tech, Mithril Capital Management, TDK Ventures, Mark Cuban.
Invirsa Inc. is a clinical-stage pharmaceutical company developing INV-102, an innovative topically administered eyedrop formulation that augments the body's response to DNA damage, improving cell stability for ocular conditions like injuries from sulphur mustard gas and infectious keratoconjunctivitis.[1][2][3] It serves patients with severe eye injuries and viral infections, addressing unmet needs in rapid treatment for DNA-damaged ocular tissues where current options fall short.[1][2] Backed by JumpStart Ventures' Evergreen Fund III and a $29.6 million, 5-year BARDA partnership, Invirsa shows strong growth momentum through government contracts and licensing deals, including a $16.9 million award for medical countermeasures.[1][2]
Founded in 2014, Invirsa emerged from research licensed from Nationwide Children's Hospital, initially targeting respiratory diseases before pivoting to ocular therapies.[1][2] The company's idea stems from advancing DNA damage response mechanisms into practical eyedrop treatments, with early traction via CincyTech announcements and a BARDA contract that fueled development.[2] Headquartered in Columbus, Ohio, Invirsa's leadership and scientific advisory board bring specialized expertise in drug innovation for high-stakes injuries like chemical exposures.[2][1]
Invirsa rides the wave of precision biomedical therapies for chemical and viral threats, amplified by rising geopolitical risks (e.g., mustard gas) and annual epidemics of ocular/respiratory infections.[2][3][4] Timing aligns with U.S. government push for medical countermeasures via BARDA, favoring rapid-response eyedrops amid global biodefense needs.[2] Market forces like underserved DNA damage treatments and scalable topical delivery give it an edge in the $100M+ viral infection space.[4] Invirsa influences the ecosystem by validating biotech for dual-use (military/civilian) applications, potentially accelerating similar DNA-repair platforms.[1][2]
Invirsa is poised for clinical milestones, with BARDA funding driving INV-102 toward FDA approval and commercialization for ocular emergencies.[2] Trends like AI-accelerated drug discovery and expanded biothreat preparedness will shape its path, potentially broadening to respiratory indications.[2][4] Its influence may grow as a model for agile biotech tackling DNA vulnerabilities, evolving from niche player to key countermeasure provider—reinforcing its role in safeguarding against both everyday infections and rare disasters.[1][3]
Invirsa has raised $10.5M across 3 funding rounds. Most recently, it raised $8.0M Series B in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $8.0M Series B | Alumni Ventures, Cincy Tech, Mithril Capital Management, TDK Ventures, Mark Cuban | |
| Dec 1, 2019 | $2.0M Series A | Alumni Ventures, Cincy Tech, Mithril Capital Management, TDK Ventures, Mark Cuban | |
| Jul 1, 2017 | $520K Seed | Alumni Ventures, Cincy Tech, Mithril Capital Management, TDK Ventures, Mark Cuban |